文献速递心脑血管急症

中等强度运动训练对肥厚型心肌病患者峰值耗氧量的影响:一项随机临床试验

Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01
一句话结论在肥厚型心肌病患者中,16周中等强度运动训练较常规活动小幅但显著提高峰值耗氧量(组间差1.27 mL/kg/min,95%CI 0.17-2.37,P=0.02),两组均未发生持续性室性心律失常、心脏骤停、适当除颤器放电或死亡。

该随机临床试验纳入136例肥厚型心肌病患者,在美国2家学术医学中心于2010年4月至2015年10月开展,随机分为16周中等强度运动训练组(n=67)或常规活动组(n=69)。主要终点为基线至16周峰值耗氧量变化,运动训练组平均增加1.35(95%CI 0.50-2.21)mL/kg/min,常规活动组增加0.08(95%CI -0.62-0.79)mL/kg/min,组间差1.27(95%CI 0.17-2.37;P=0.02)。两组均未发生持续性室性心律失常、心脏骤停、适当除颤器放电或死亡。作者认为该初步研究显示中等强度运动较常规活动在16周时带来统计学显著但幅度较小的运动能力提升,需进一步研究其临床意义及中等及以上强度运动的长期安全性。

要点

  • 在肥厚型心肌病成人中,16周中等强度运动训练使峰值耗氧量平均增加1.35 mL/kg/min(95%CI 0.50-2.21),常规活动组增加0.08 mL/kg/min(95%CI -0.62-0.79)。
  • 组间峰值耗氧量差异为1.27 mL/kg/min(95%CI 0.17-2.37;P=0.02),运动训练组优于常规活动组。
  • 两组均未发生持续性室性心律失常、心脏骤停、适当除颤器放电或死亡。
  • 作者认为该研究为初步研究,中等强度运动带来的运动能力提升幅度较小,需进一步研究其临床重要性及中等及以上强度运动的长期安全性。
  • 研究纳入136例患者,平均年龄50.4岁(SD 13.3),42%为女性,113例(83%)完成研究。

适用人群与场景

  • 成人肥厚型心肌病患者,随机分组时纳入136例,平均年龄50.4岁(SD 13.3),42%为女性。
  • 研究在美国2家学术医学中心(密歇根大学健康系统和斯坦福大学医学中心)开展,纳入时间为2010年4月至2015年10月,末次随访日期为2016年11月。

处置流程与药物剂量

  • 运动训练组接受16周中等强度运动训练(n=67);对照组接受常规活动(n=69)。

研究设计与关键结果

  • 随机临床试验,纳入136例肥厚型心肌病患者,随机分为16周中等强度运动训练组(n=67)或常规活动组(n=69),113例(83%)完成研究。
  • 主要终点:基线至16周峰值耗氧量变化,运动训练组平均增加1.35 mL/kg/min(95%CI 0.50-2.21),常规活动组平均增加0.08 mL/kg/min(95%CI -0.62-0.79),组间差1.27 mL/kg/min(95%CI 0.17-2.37;P=0.02)。
  • 两组均未发生持续性室性心律失常、心脏骤停、适当除颤器放电或死亡。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 作者指出该研究为初步研究,需要进一步研究以理解该发现对肥厚型心肌病患者的临床重要性,以及中等及以上强度运动的长期安全性。

对床旁实践的改变

  • 作者认为,在肥厚型心肌病患者中,中等强度运动较常规活动在16周时带来统计学显著但幅度较小的运动能力提升,需进一步研究其临床重要性及中等及以上强度运动的长期安全性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Formulating exercise recommendations for patients with hypertrophic cardiomyopathy is challenging because of concern about triggering ventricular arrhythmias and because a clinical benefit has not been previously established in this population.

OBJECTIVE: To determine whether moderate-intensity exercise training improves exercise capacity in adults with hypertrophic cardiomyopathy.

DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial involving 136 patients with hypertrophic cardiomyopathy was conducted between April 2010 and October 2015 at 2 academic medical centers in the United States (University of Michigan Health System and Stanford University Medical Center). Date of last follow-up was November 2016.

INTERVENTIONS: Participants were randomly assigned to 16 weeks of moderate-intensity exercise training (n = 67) or usual activity (n = 69).

MAIN OUTCOMES AND MEASURES: The primary outcome measure was change in peak oxygen consumption from baseline to 16 weeks.

RESULTS: Among the 136 randomized participants (mean age, 50.4 [SD, 13.3] years; 42% women), 113 (83%) completed the study. At 16 weeks, the change in mean peak oxygen consumption was +1.35 (95% CI, 0.50 to 2.21) mL/kg/min among participants in the exercise training group and +0.08 (95% CI, -0.62 to 0.79) mL/kg/min among participants in the usual-activity group (between-group difference, 1.27 [95% CI, 0.17 to 2.37]; P = .02). There were no occurrences of sustained ventricular arrhythmia, sudden cardiac arrest, appropriate defibrillator shock, or death in either group.

CONCLUSIONS AND RELEVANCE: In this preliminary study involving patients with hypertrophic cardiomyopathy, moderate-intensity exercise compared with usual activity resulted in a statistically significant but small increase in exercise capacity at 16 weeks. Further research is needed to understand the clinical importance of this finding in patients with hypertrophic cardiomyopathy, as well as the long-term safety of exercise at moderate and higher levels of intensity.

TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01127061.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Saberi S, Wheeler M, Bragg-Gresham J, et al. Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JAMA. 2017. PMID: 28306757. doi:10.1001/jama.2017.2503

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。